L-DOPA therapy past, present and future
Barbeau, A.
Arizona Medicine 27(7): 1-4
1970
ISSN/ISBN: 0004-1556 PMID: 5432715 Document Number: 22621
Document emailed within 1 workday
Related Documents
Wolf, J.E. 2005: Present and future rosacea therapy Cutis 75(3 Suppl): 4-7; Discussion: 33-36Peters, B.S.; Conway, K. 2011: Therapy for HIV: past, present, and future Advances in Dental Research 23(1): 23-27
Eugui, E.M. 2000: Present and future of immunosuppressive therapy Medicina 60(1): 67-80
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Motohashi, N. 2004: Electroconvulsive therapy: past, present, and future Seishin Shinkeigaku Zasshi 106(5): 537-545
Gupta, A.K.; Uro, M.; Cooper, E.A. 2010: Onychomycosis therapy: past, present, future Journal of Drugs in Dermatology: Jdd 9(9): 1109-1113
Karapita, A.D. 1980: Intravenous therapy: past present and future Dimensions in Health Service 57(5): 20-23
Galkin, V.A. 1998: Past, present and future of outpatient therapy Terapevticheskii Arkhiv 70(9): 23-24
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Kahan, B.D. 1993: Cyclosporine: the base for immunosuppressive therapy--present and future Transplantation Proceedings 25(1 Part 1): 508-510
Acharya, V.N. 2012: Stem cell therapy for kidney disease--present and future Journal of the Association of Physicians of India 60: 32-33
Everard, M.L. 2000: Aerosol therapy past, present, and future: a clinician's perspective Respiratory Care 45(6): 769-776
Nagai, M.; Arai, T. 1982: Interferon therapy for malignant brain tumors-present and future No Shinkei Geka. Neurological Surgery 10(5): 463-476
Akaza, H.; Saijo, N.; Aiba, K.; Isonishi, S.; Ohashi, Y.; Kawai, K.; Konishi, T.; Saeki, T.; Sone, S.; Tsukagoshi, S.; Tsuruo, T.; Noguchi, S.; Miki, T.; Mikami, O.; Smith, M.; Hoctin-Boes, G.; Stribling, D. 2001: Platinum compounds in cancer therapy--past, present, and future Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(5): 625-635
Kato, H.; Yamaguchi, T.; Saisho, H.; Tsujii, H. 1996: Present state and future of radiation therapy for pancreatic cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(12): 1642-1646
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Pitule, P.; Liska, V.; Treska, V.; Novák, P.; Cedíková, M.; Králícková, M. 2011: Contribution of molecular biology to the diagnosis and therapy of colorectal carcinoma--the present and future Rozhledy V Chirurgii: Mesicnik Ceskoslovenske Chirurgicke Spolecnosti 90(6): 315-323
Purcell, H. 1994: Present and future possibilities in the use of calcium antagonists in the therapy of cardiovascular diseases with special emphasis on amlodipine Vnitrni Lekarstvi 40(8): 545
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713